Advertisement

Advertisement

Breast Cancer

Effect of Virtual Tumor Board Implementation on Use of Whole-Breast Hypofractionated Radiation Therapy

In an observational cohort study reported in JCO Oncology Practice, Powell et al found that the use of whole-breast hypofractionated radiotherapy increased among patients with breast cancer with health insurance plans from one national health-care organization after the implementation of a virtual...

Breast Cancer

Are Delays in Breast Cancer Treatment as Harmful as Commonly Thought?

Delays in the treatment of breast cancer matter, but not as much “as we and our patients typically assume,” Richard J. Bleicher, MD, FACS, informed participants at the 22nd Annual Lynn Sage Breast Cancer Symposium.1 Some of these delays are unavoidable and others are tradeoffs that must be made to...

Breast Cancer

Final Efficacy Results From the ExteNET Trial: Neratinib in Pretreated Patients With HR-Positive, HER2-Positive Early Breast Cancer

In an analysis from the phase III ExteNET trial reported in Clinical Breast Cancer, Arlene Chan, MD, and colleagues found significant improvements in efficacy outcomes with the administration of neratinib vs placebo starting at 1 year or sooner after neoadjuvant/adjuvant trastuzumab-based therapy...

Breast Cancer
Issues in Oncology

Limited English-Language Proficiency May Affect Frequency of Screening Mammograms

Limited English-language proficiency may be a risk factor for receiving screening mammograms less often, according to new study results using national data. These findings, concerning women age 40 and older living in the United States, were presented at the American College of Surgeons Clinical...

Breast Cancer
Immunotherapy

Addition of Atezolizumab to T-DM1 in Previously Treated Patients With HER2-Positive Advanced Breast Cancer

In the phase II KATE2 trial reported in The Lancet Oncology, Leisha A. Emens, MD, and colleagues found that the addition of atezolizumab to ado-trastuzumab emtansine (T-DM1) did not improve progression-free survival in patients with advanced HER2-positive breast cancer progressing after previous...

breast cancer
covid-19

Melissa K. Accordino, MD, on Breast Cancer Care Delivery: Impact of the COVID-19 Pandemic

Melissa K. Accordino, MD, of Columbia University Medical Center, discusses findings showing nearly half of the patients with breast cancer treated at an academic center in New York City experienced a change or delay in their workup or treatment during the COVID-19 pandemic. Race and socioeconomic factors played a significant role (Abstract 88).

Breast Cancer

Clinical Challenges of Managing Breast Cancer Brain Metastases

“Breast cancer brain metastases are a clinical challenge that are only increasing in incidence and are a consequence of advanced breast cancers, largely HER2-positive and triple-negative,” according to Carey K. Anders, MD, Professor of Medicine and Medical Director of the Duke Brain and Spine...

Issues in Oncology
Breast Cancer

Do Hospitals That Primarily Serve Minority Patients Offer Standard Surgical Care for Patients With Breast Cancer?

Among accredited cancer centers in the United States, hospitals serving primarily minority patients are as likely as other hospitals to offer the standard of surgical care for early-stage breast cancer, according to results presented at the virtual American College of Surgeons Clinical Congress...

Breast Cancer
Symptom Management

Can Routine Scans Help Predict Which Patients With Breast Cancer May Be at Risk for Heart Disease?

Automated analysis of the routine scans of patients with breast cancer may help to predict which women have a greater risk of developing cardiovascular disease, according to research presented by Gal et al at the 12th European Breast Cancer Conference (Abstract 7). Women who have been treated for...

Breast Cancer
Immunotherapy

NeoALTTO Trial: Final Analysis Examines Neoadjuvant Lapatinib/Trastuzumab in HER2-Positive Breast Cancer

Final analysis of results from a randomized clinical trial of lapatinib and trastuzumab given before surgery in patients with early HER2-positive breast cancer has found that women who had a pathologic complete response survived longer without cancer recurrence than patients who did not. This was...

Breast Cancer

Addition of Veliparib to Carboplatin/Paclitaxel in BRCA-Mutated Advanced Breast Cancer

As reported in The Lancet Oncology by Véronique Diéras, MD, of the Institut Curie, Paris, and Centre Eugène Marquis, Rennes, and colleagues, the phase III BROCADE3 trial has shown a significant improvement in progression-free survival with the addition of the poly (ADP-ribose) polymerase (PARP)...

Issues in Oncology
Breast Cancer
Colorectal Cancer
Lung Cancer
Genomics/Genetics
Multiple Myeloma
Pancreatic Cancer

Trends to Watch in Early-Onset Cancer Among Young Adults

Although cancer incidence and mortality rates for all cancers combined are considerably lower in younger adults than older adults, a disturbing pattern is beginning to emerge in the development of early-onset cancers, typically diagnosed in older patients, occurring in younger adults. The rising...

Breast Cancer
Pain Management

Eliminating Routine Opioids While Maintaining Pain Control for Women Undergoing Lumpectomy or Excisional Biopsy

Changing from routinely prescribing opioids for patients who were having a lumpectomy or excisional biopsy to instead routinely prescribing nonsteroidal anti-inflammatory drugs [NSAIDs] resulted in a sharply decreased opioid prescription rate with “no difference in the proportion of patients...

Breast Cancer

Expert Point of View: George W. Sledge, Jr, MD

The results of monarchE were discussed by George W. Sledge, Jr, MD, Professor of Medicine and Chief of Oncology at Stanford University Medical Center, who offered some possibilities as to why its results were positive and those for palbociclib, in the phase III PALLAS trial, were “resoundingly...

Breast Cancer

Addition of Abemaciclib to Endocrine Therapy Reduces Recurrence in Early Breast Cancer

For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has reduced the risk of invasive disease recurrence in patients with early breast cancer when combined with standard endocrine therapy, investigators reported at the European Society for Medical Oncology (ESMO) Virtual...

Breast Cancer

Phase III NALA Trial Meets Primary Endpoint in Previously Treated HER2-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Cristina Saura, MD, of Vall d’Hebron University Hospital, Barcelona, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with the irreversible pan-HER tyrosine kinase inhibitor neratinib plus...

Breast Cancer

Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases

For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), no single regimen is an established standard of care. More than 50% of these patients will develop brain metastasis, and thus far, treatments...

Breast Cancer

Managing Breast Cancer in a Pregnant Patient

“One of themost challenging oncologic situations is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Associate Dean, Regulatory Affairs; Director of the Breast Care Center; and Professor of Surgery, Pathology, and Biomedical Engineering at the University of...

Breast Cancer

High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options

Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...

Breast Cancer

HER2-Positive Metastatic Breast Cancer Highlights 2019–2020 Almanac

The past 2 years have seen a dramatic change in the standard of care for patients with HER2-positive metastatic breast cancer whose disease has progressed on trastuzumab. Promising new agents and combinations for later lines of therapy may also challenge current treatment strategies, according to...

Breast Cancer

Retrospective Analysis From the BIG 2-98 Trial of Adjuvant Docetaxel-Based Chemotherapy for Early Breast Cancer

A retrospective analysis from the BIG 2-98 trial reported in the Journal of Clinical Oncology by Christine Desmedt, PhD, of the Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Belgium, and colleagues showed poorer disease-free and overall survival with...

Breast Cancer

Long-Term Evaluation of Treatment Efficacy After Primary DCIS Diagnosis

A long-term study of women with ductal carcinoma in situ (DCIS) has shown that surgery to remove the tissue followed by radiotherapy may lower the risk of subsequent cancer compared to surgery alone. The study, presented at the 12th European Breast Cancer Conference by van Seijen et al (Abstract...

Breast Cancer

Breast Cancer Risk After Benign Breast Disease

Benign breast disease is known to increase the chances of subsequent breast cancer. According to Spanish researchers, the way benign breast disease is detected may be an indication of how likely it is to become cancerous. The findings from the team led by Xavier Castells, MD, PhD, Head of the...

Breast Cancer

Novel Indications and New Drugs for the Treatment of Patients With Breast Cancer

Over the past year (December 2019–September 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for therapeutic agents used in breast cancer. Pertuzumab/Trastuzumab/Hyaluronidase-zzxf On June 29, 2020, the FDA approved a new fixed-dose...

Breast Cancer

Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer

In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...

Breast Cancer

Tucatinib Combination in Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases

In an analysis of the pivotal phase III HER2CLIMB trial reported at the ASCO20 Virtual Scientific Program, Nancy U. Lin, MD, of Dana-Farber Cancer Institute, Boston, and colleagues found that tucatinib, a small-molecule tyrosine kinase inhibitor that is highly selective for HER2, plus...

Breast Cancer

Local Recurrence With Radiation Boost in HER2-Positive Breast Cancer: HERA Trial Analysis

In a retrospective analysis reported in the International Journal of Radiation Oncology • Biology • Physics, Joseph Abi Jaoude, MD, of the American University of Beirut Medical Center, and colleagues found that a radiation boost did not reduce the risk of local recurrence among women with...

Breast Cancer

Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents

New agents for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...

Breast Cancer

Updates From Additional Clinical Trials in HER2-Positive Breast Cancer

Here we present summaries of several additional clinical trials in HER2-positive breast cancer reported over the past year. Jame Abraham, MD, Chair of the Division of Hematology and Oncology at the Taussig Cancer Center, Cleveland Clinic, shared his perspective on several of these trials presented ...

Breast Cancer

Phase III SOPHIA Trial Evaluates Margetuximab/Chemotherapy vs Trastuzumab/Chemotherapy for HER2-Positive Breast Cancer

The second interim analysis of the phase III SOPHIA trial demonstrated a significant, though modest, improvement in progression-free survival, response rate, and clinical benefit with the addition of margetuximab to chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive...

Breast Cancer

Abemaciclib/Fulvestrant/Trastuzumab for Patients With Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer

In the phase II monarcHER trial reported in The Lancet Oncology, Sara M. Tolaney, MD, of Dana-Farber Cancer Institute, Boston, and colleagues, found that the combination of abemaciclib, fulvestrant, and trastuzumab prolonged progression-free survival vs trastuzumab plus standard-of-care...

Breast Cancer

Neratinib in Previously TreatedHER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial

Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...

Breast Cancer

Patient Experiences of Acute Toxicity From Breast Radiotherapy According to Fractionation Scheme

In a study reported in the Journal of Clinical Oncology, Reshma Jagsi, MD, DPhil, and colleagues found differences in patient reports of acute toxicities according to fractionation scheme of whole-breast radiotherapy for breast cancer, with pain being reported more frequently in Black vs White...

Breast Cancer
Immunotherapy

Expert Point of View: Lisa A. Carey, MD

Invited study discussant Lisa A. Carey, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research and Deputy Director of Clinical Sciences at the University of North Carolina-Chapel Hill, framed her remarks as a tale of two trials. Dr. Carey asked these...

Breast Cancer
Immunotherapy

IMpassion131: No Benefit for Atezolizumab Plus Paclitaxel in Triple-Negative Breast Cancer

Based on some unexpected negative results, oncologists using atezolizumab for metastatic triple-negative breast cancer should pair it with nab-paclitaxel, not paclitaxel. In contrast to the overall survival benefit shown for atezolizumab plus nab-paclitaxel in the previous IMpassion130...

Immunotherapy
Multiple Myeloma
Lymphoma
Gastroesophageal Cancer
Gastrointestinal Cancer
Breast Cancer

FDA Pipeline: Priority Review for Agents in Multiple Myeloma, Anaplastic Large Cell Lymphoma

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to therapies for pretreated patients with multiple myeloma and pediatric patients with ALK-positive anaplastic large cell lymphoma; granted Fast Track designation to novel agents in gastric/gastroesophageal junction...

Breast Cancer
Geriatric Oncology

Adjuvant Trastuzumab With or Without Chemotherapy for Older Patients With HER2-Positive Early Breast Cancer

In the Japanese RESPECT trial reported in the Journal of Clinical Oncology, Sawaki et al found that noninferiority of adjuvant trastuzumab alone vs with chemotherapy was not shown for disease-free survival among women with HER2-positive breast cancer between the ages of 70 and 80 years. However, a...

Breast Cancer
Immunotherapy

Addition of Atezolizumab to Neoadjuvant Chemotherapy in Early-Stage Triple-Negative Breast Cancer: IMpassion031 Trial

As reported in The Lancet by Elizabeth A. Mittendorf, MD, and colleagues, results from the phase III IMpassion031 trial showed improved pathologic complete response rates with the addition of atezolizumab to sequential nab-paclitaxel and anthracycline-based neoadjuvant chemotherapy in patients with ...

Breast Cancer

Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With Early Breast Cancer at High Risk of Recurrence: monarchE Trial

As reported in the Journal of Clinical Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, the phase III monarchE trial has shown that adjuvant abemaciclib plus endocrine therapy significantly improved invasive disease–free survival vs endocrine therapy alone in patients with hormone...

breast cancer
symptom management

Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study

Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients with breast cancer receiving chemotherapy. Although the telehealth program was associated with fewer grade 3 toxicities and a slight decline in quality of life, it did not lead to fewer emergency department visits and hospitalizations (Abstract LBA87).

breast cancer
immunotherapy

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Paclitaxel, Nab-paclitaxel, and Atezolizumab in IMpassion Trials

Lisa A. Carey, MD, of the University of North Carolina, discusses phase III results from two IMpassion trials, 130 and 131, which explored, respectively, atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer and first-line paclitaxel with or without atezolizumab for unresectable disease (Abstracts LBA15 and LBA16).

breast cancer
immunotherapy

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses results from the phase III ASCENT trial, which showed the antibody-drug conjugate sacituzumab govitecan-hziy improved progression-free and overall survival more than standard single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract LBA17).

Breast Cancer

Breast Induration With Hypofractionated vs Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma in Situ

In a Danish Breast Cancer Group phase III trial (DBCG HYPO) reported in the Journal of Clinical Oncology, Offersen et al found no difference in the rates of breast induration with moderately hypofractionated vs standard fractionated radiotherapy in women with early breast cancer or ductal carcinoma ...

Breast Cancer

Effect of Mammography Screening From Age 40 on Breast Cancer Mortality in the UK Age Trial

As reported in The Lancet Oncology by Stephen W. Duffy, MSc, of the Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, and colleagues, final results of the UK Age Trial show that initiation of annual mammography screening for breast cancer at...

Breast Cancer

New Breast Cancer Agents and Concurrent Radiation: Risk or Benefit?

Most of the newer systemic treatments for breast cancer can be safely and effectively paired with radiation therapy—although there are some exceptions, according to Mylin A. Torres, MD, the Louisa and Rand Glenn Family Chair in Breast Cancer Research and Associate Professor of Radiation Oncology at ...

Breast Cancer

Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial

Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...

Breast Cancer
Immunotherapy

Phase III NALA Trial Meets Primary Endpoint in Previously Treated HER2-Positive Breast Cancer

As reported in the Journal of Clinical Oncology by Cristina Saura, MD, of Vall d’Hebron University Hospital, Barcelona, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with the irreversible pan-HER tyrosine kinase inhibitor neratinib plus...

Breast Cancer

Age at Diagnosis May Improve Risk Stratification for Patients With Breast Cancer

Age is not just a number when it comes to prognosis for invasive breast cancer. According to data presented during the 2020 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, age at diagnosis of breast cancer is a highly prognostic clinical variable that warrants...

breast cancer

Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone

Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in the metastatic setting with palbociclib plus endocrine therapy did not translate into the earlier adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer. Long-term follow-up is ongoing (Abstract LBA12).

Breast Cancer
Genomics/Genetics

Use of ctDNA to Direct Therapy in Advanced Breast Cancer

In the phase IIa plasmaMATCH platform trial reported in The Lancet Oncology, Nicholas C. Turner, MD, and colleagues found that circulating tumor DNA (ctDNA) provided accurate genotyping that permitted selection of directed therapies in patients with advanced breast cancer. Study Details The...

Advertisement

Advertisement

Advertisement